Lorviqua fails to receive reimb as first-line therapy

By Lee, Tak-Sun | translator Kang, Shin-Kook

24.06.04 05:44:12

가나다라 0

Lorviqua conditionally passed DREC review in January but failed pricing negotiations

Demonstrated high survival rates as first-line therapy at ASCO…company plans to reattempt reimbursement listing

The reimbursement extension application for Lorviqua, a treatment for anaplastic lymphoma kinase (ALK)-positive non-small-cell cancer, has failed to go beyond the negotiation stage with the National Health Insurance Service.

With the breakdown of the negotiations, the company will have to start over from the application stage for Lorviqua’s reimbursement

According to industry sources, Pfizer Korea’s recent negotiations with the National Health Insurance Service for Lorviqua’s reimbursement(NHIS) fell through.

Lorviqua is a treatment for ALK (anaplastic lymphoma kinase) positive non-small cell lung cancer, that was listed for reimbursement in September 2022. The d

Lee, Tak-Sun(hooggasi2@dailypharm.com)

If you want to see the full article, please JOIN US (click)